SavedAdd your journal

Journals / Arşiv Kaynak Tarama Dergisi / 2019 / Cilt: 28 - Sayı: 1

Chelation therapy and Chelating Ligands for Iron Overload

Demir Fazlalığı İçin Şelasyon Tedavisi ve Şelasyon Ligandları

Abdullah TULİ
Gülüzar ÖZBOLAT
Pages
66–81
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we tried to give information about the reasons for the occurrence of iron overload in the human body, the latest developments in chelators and chelators that are in the trial phase at the clinic.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Iron overload is a condition of excess iron stores in different parts of body which can be largely prevented by the use of chelating agents.
📊
Key Findings & Data:The human body doesn’t have any a physiological mechanism to eliminate iron overload.
💡
Conclusion & Impact:In this review, we tried to give information about the reasons for the occurrence of iron overload in the human body, the latest developments in chelators and chelators that are in the trial phase at the clinic.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Iron overload is a condition of excess iron stores in different parts of body which can be largely prevented by the use of chelating agents. The human body doesn’t have any a physiological mechanism to eliminate iron overload. Currently applied methods for treatment of iron overload consisting of chelation therapy. Iron chelation therapy involves the use of ligating drugs that avidly bind iron for the treatment of potentially iron overload disease. In this review, we tried to give information about the reasons for the occurrence of iron overload in the human body, the latest developments in chelators and chelators that are in the trial phase at the clinic.

Özet

Demir fazlalığı büyük ölçüde şelatlama ajanları kullanılarak önlenebilen, vücudun farklı bölgelerinde demirin fazlaşekilde depolanma durumudur. İnsan vücudu demir fazlalığını gidermek için fizyolojik bir mekanizmaya sahip değildir.Demir fazlalığının tedavisi için şu an uygulanan yöntem şelasyon tedavisidir. Demir şelasyon tedavisi, potansiyel olarakdemir fazlalığı hastalığının tedavisinde demire bağlanan ligandların kullanımını içerir. Bu derlemede insanda demirfazlalığı oluşma nedenleri ve oluşması durumunda kullanılan şelatörler ve klinikte deneme aşamasında olan şelatörlerile ilgili son gelişmeleri bilgi vererek aktarmaya çalıştık.

🔖

Cite This Article

TULİ, A., ÖZBOLAT, G. (2022). Chelation therapy and Chelating Ligands for Iron Overload. Arşiv Kaynak Tarama Dergisi, Cilt: 28 - Sayı: 1, 66–81. https://ajindex.com/articles/449151

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (21)

  1. Flora SJS, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health. 2010;7:2745-88
  2. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalianiron metabolism. Cell. 2004;117:285-97
  3. Richardson DR. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematology. 2002;42:267- 81
  4. Winter WE, Bazydlo LA, Harris NS. The moleculer biology of human iron metabolism. Laboratory Medicine. 2014; 45:92- 102
  5. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Cancer. 2013;13:342-55
  6. Chen JJ, Luo ZD, Zhao ZN, Xie LN, Zheng WJ, Chen TF. Cellular localization of iron(II) polypyridyl complexes determines their anticancer action mechanisms. Biomaterials, 2015;71:168-77
  7. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005;57:547-83
  8. Crisponi G, Remelli M. Iron chelating agents for the treatment of iron overload. Coord. Chem. Rev. 2008;252:1225-40
  9. Angelucci E, Brittenham GM, McLaren CE. Hepatic iron concentration and total body iron stores in Thalassemia Major. N Engl. J Med. 2000;343:327-31
  10. Olivieri NF. The β thalassemias. N Engl J Med., 1999;341:99-109
  11. Hershko C, Konijin AM, Link G. Iron chelators for thalasaemia. Br J Haematol. 1998;101:399-406
  12. Faa G, Crisponi G. Iron chelating agents in clinical practice. Coordination Chemistry. 1999;184:291-310
  13. Liu ZD, Hider RC. Design of clinically usefull iron (III)-selective chelators. Med.Res Rev. 2002;22:26-64
  14. Whetherall DJ. Pathophysiology of thalassemia. Bailliére’s Clinical Hematology. 1998;11:127-46
  15. Ganz T. Hepcidin in iron metabolism. Current Opinion in Hemayology. 2004;11:251-4
  16. Feng M, Does LV, Bantjees A. Iron(III) chelating resins. VI. Stability constants of iron(III)-ligand complexes on insoluble polymeric matrices. Journal of Applied polymer Science. 1994;56:1231-7
  17. Ellis J. Neufeld oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107:3436-41
  18. Faa G, Crisponi G. Iron chelating agents in clinical practice. Coordination Chemistry Reviews.1999;184:291-310
  19. Beutler E. Hemochromatosis: genetics and pathophysiology. Annu Rev Med., 2006;57:331-47
  20. Weinberg ED. Iron loading and disease surveillance. Emerg Infect Dis., 1999;5:346-52
  21. Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology